Energy Balance, Myostatin, and GILZ: Factors Regulating Adipocyte Differentiation in Belly and Bone

Xingming Shi, 1, 2 Mark Hamrick, 1, 3 and Carlos M. Isales 1, 4

1 Institute of Molecular Medicine and Genetics, Medical College of Georgia, GA 30912, USA
2 Department of Pathology, Medical College of Georgia Hospital, GA 30912, USA
3 Department of Cellular Biology and Anatomy, Medical College of Georgia, GA 30912, USA
4 Department of Orthopaedic Surgery, Medical College of Georgia, GA 30912, USA

Correspondence should be addressed to Carlos M. Isales, cisales@mcg.edu

Received 9 July 2007; Accepted 16 August 2007

Recommended by Z. Elizabeth Floyd

Peroxisome proliferator-activated receptor gamma (PPAR-γ) belongs to the nuclear hormone receptor subfamily of transcription factors. PPARs are expressed in key target tissues such as liver, fat, and muscle and thus they play a major role in the regulation of energy balance. Because of PPAR-γ’s role in energy balance, signals originating from the gut (e.g., GIP), fat (e.g., leptin), muscle (e.g., myostatin), or bone (e.g., GILZ) can in turn modulate PPAR expression and/or function. Of the two PPAR-γ isoforms, PPAR-γ2 is the key regulator of adipogenesis and also plays a role in bone development. Activation of this receptor favors adipocyte differentiation of mesenchymal stem cells, while inhibition of PPAR-γ2 expression shifts the commitment towards the osteoblastogenic pathway. Clinically, activation of this receptor by antidiabetic agents of the thiazolidinedione class results in lower bone mass and increased fracture rates. We propose that inhibition of PPAR-γ2 expression in mesenchymal stem cells by use of some of the hormones/factors mentioned above may be a useful therapeutic strategy to favor bone formation.

Copyright © 2007 Xingming Shi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. INTRODUCTION

The peroxisome proliferator-activated receptor gamma (PPAR-γ) family of transcription factors belongs to the nuclear hormone receptor subfamily of transcription factors that can bind to specific DNA response elements in the regulatory regions of target genes. Other isotypes of this family include PPAR alpha (PPAR-α) and PPAR beta/delta (PPAR-β/δ). Each of these isotypes is encoded by a different gene and has different functions and different tissue distribution [1]. Many excellent reviews have been published recently on the regulation of nuclear receptors belonging to the PPAR family [2–12] and the reader is referred to one of these reviews for an overview on these nuclear receptors.

The current review more narrowly focuses on PPAR-γ2, its role in bone formation, and its regulation by the energy state. Bone, like other tissues in the body, requires a positive energy balance to grow. However, even with a positive energy balance, bone progenitor cells can differentiate into osteoblast, adipocyte, or muscle cells. PPAR-γ2 is a key regulator of this differentiation step in bone marrow progenitor cells. Tissues in the body important in regulating this energy balance include skeletal muscle, adipocytes, and liver (see Figure 1). The crosstalk between these target tissues occurs via both central nervous system (CNS) output and peripheral hormones from enteric, pancreatic, or adipocytic sources. Studies from our laboratories have focused on enteric hormones like glucose-dependent insulinotropic peptide (GIP), adipocytic hormones like leptin, and skeletal muscle-derived factors such as myostatin in addition to transcriptional regulators such as the glucocorticoid-induced leucine zipper (GILZ) in the regulation of osteoblast/adipocyte differentiation from bone marrow progenitor cells. The impact of changes in the organism’s energy balance on mesenchymal stem cell differentiation will be discussed in more detail below.

2. PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR

PPAR-γ is highly expressed in adipose tissue although it is also expressed in other tissues including skeletal muscle,
and there are two protein products, PPAR-γ intestine, endothelium, prostate, and white blood cells [13]. The gene for PPAR-γ is localized on chromosome 3 [13] and there are two protein products, PPAR-γ1 and PPAR-γ2, which are isoforms transcribed from the same gene with different promoter usage [14, 15]. PPAR-γ2 is predominantly expressed in adipose tissue, while PPAR-γ1 is more widely expressed [10]. Of these two isoforms, PPAR-γ2 is a key regulator of adipogenesis [16–18] and is expressed at an early stage of the adipogenesis program [19]. PPAR-γ2 can activate a battery of genes necessary for lipid metabolism, including lipoprotein lipase (LPL) [20], phosphoenolpyruvate carboxykinase (PEPCK) [21], fatty acid-binding and transport proteins [22], and stearoyl-CoA desaturase-1 (SCD-1) [23]. Functional PPAR response elements (PPREs) have been identified in the promoter regions of these genes. In addition, activation of PPAR-γ2 by its ligand [24, 25] induces cell cycle withdrawal and terminal adipocyte differentiation in a variety of mesenchymal cell lines [26–29]. Thus, the pivotal regulatory role that PPAR-γ2 plays in adipocyte differentiation is recognized by its early and tissue-specific expression [19] and its ability to direct fibroblasts and myoblasts to differentiate into adipocytes when it is ectopically expressed in these cells [28, 30].

Most importantly, a recent in vivo study has demonstrated that PPAR-γ insufficiency in mice (PPAR-γ−/−) results in a dramatic decrease (by 50%) in adipogenesis with a concomitant increase in osteogenesis through osteoblast formation from marrow progenitors [31]. This study suggests the possibility of interrupting the PPAR-γ pathway as a novel treatment of osteoporosis.

3. **MESENCHYMAL STEM CELLS**

Mesenchymal stem cells (MSCs) are multipotent cells that, under appropriate culture conditions, can differentiate into multiple cell lineages, including osteoblasts, myoblasts, and adipocytes [32–35]. Considerable evidence has shown that the commitment between osteoblast and adipocyte lineages from MSCs is reciprocal, that is, when the adipogenic pathway is blocked, MSCs enter the osteogenic pathway, and vice versa [36–40]. Increased marrow adipogenesis negatively impacts bone formation because mesenchymal precursor cells are directed towards the adipocyte lineage rather than to the osteoblast lineage [41, 42]. Marrow adipocytes can also inhibit osteoblast proliferation in vitro, and adipocytes secrete factors such as IL-6 and TNFα [43] that stimulate the differentiation of the bone-resorbing cells, osteoclasts [44]. The negative impact of marrow adipogenesis on bone health is further indicated by the fact that bone formation rate is inversely correlated with adipocyte number in bone biopsies of adult men and women [45], and women with osteoporosis have higher number of marrow adipocytes than those with healthy bone [46].

Clinically, much recent attention has focused on drugs belonging to the thiazolidinedione class. These medications (e.g., rosiglitazone and pioglitazone) are PPAR agonists used to treat patients with diabetes mellitus, and have recently been associated with impaired bone quality, increased marrow fat, and increased fracture rates [47, 48].

Understanding the regulators of MSC differentiation between fat and bone has gained increasing importance with increasing human longevity since, as humans age, the number of adipocytes increases and the number of osteoblasts decreases resulting in weakened bone, age-related osteoporosis, and fragility fractures. Because of the importance of PPAR-γ2 in MSC differentiation into adipocytes or osteoblasts, we will briefly discuss some of the regulators of the PPAR-γ2 receptor.

4. **REGULATION OF THE PPAR-γ RECEPTOR**

Regulation of the PPAR-γ receptor activity can occur via (1) changes in receptor expression levels or (2) changes in transcriptional activity (see Figure 2).

A number of transcription factors can either positively or negatively modulate PPAR-γ receptor expression in adipocytes [49]. Major transcription factors activating PPAR-γ receptor expression include CCAAT/enhancer-binding protein (C/EBP) family of transcription factors and these have been reviewed extensively elsewhere [2, 50]. Although GATA-1, -2, Wnt (Wnt10b), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and transforming growth factor beta (TGF-β) play important roles in PPAR-γ regulation, they will not be discussed in this review.

PPAR-γ receptor transcriptional activity is regulated by two distinct processes: repression of receptor activity by phosphorylation (by kinases such as mitogen-activated protein, MAP kinases, which activate Jun N-terminal kinase, or JNK, and extracellular signal-regulated kinase 2, or ERK-2) and increased receptor activity by ubiquitination. Agonists for the nuclear PPAR-γ receptor include protein kinase A, natural fatty acids, eicosanoids, and oxidized lipoproteins. Less well studied are negative regulators of the nuclear PPAR-γ receptor. Activators of MAPK and thus inhibitors of PPAR-γ receptor transcriptional activity include growth factors like epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factor β’s (TGF-β’s) 1 and 2, and GILZ. Both insulin and glucocorticoid induce the expression of C/EBP-β and -δ, which in turn induce the expression of PPAR-γ and C/EBP-α and initiate the adipogenesis program.

5. **NUTRITION-RELATED HORMONES**

Enteric hormones represent the mechanism by which ingested nutrients are distributed to the various tissues in the body so as to maximize their utilization. These hormones play a key role in regulating the energy balance, in part through modulation of PPAR expression. In fact, elevation of incretin hormones, through use of inhibitors of the enzyme that breaks them down (DPP-IV inhibitors), has been shown to increase PPAR expression in the kidney [51].

Nutritional hormones are also known to be important in bone turnover as evidenced by the fact that as soon as a meal is ingested, bone breakdown is suppressed. Many nutrition-related hormones have been shown to have effects on bone turnover through in vitro or in vivo studies including (a) *Intestinal Hormones* such as (1) GIP, (2) Ghrelin, and (3)
Glucagon-like peptide-2 (GLP-2); (b) Pancreatic Hormones such as (1) Insulin, (2) Amylin, (3) Adrenomedullin, and (4) Preptin; (c) Adipocytely-secreted Hormones such as (1) Leptin, (2) Adiponectin, and (3) Resistin, as recently reviewed by Clowes et al. [52] and Reid et al. [53]. For purposes of this review, we will focus more extensively on GIP and leptin but discuss these other hormones briefly below.

5.1. Intestinal hormones

Ghrelin is a 28-amino acid peptide expressed predominantly in the gastric epithelium and small intestine, though it is also expressed to a lower extent in the brain, pancreatic islets, adrenal cortex, kidney, and bone [54]. Ghrelin's physiologic function is to stimulate growth hormone secretion, and systemic elevations of ghrelin stimulate food intake and weight gain. Ghrelin's systemic effects on energy metabolism appear to oppose those of leptin. Ghrelin receptors are expressed on osteoblasts and ghrelin stimulates osteoblastic proliferation and differentiation [55, 56]. In addition, intraperitoneal infusion of ghrelin for four weeks resulted in significant increases in bone mineral density in Sprague-Dawley rats [55]. Ghrelin levels have a significant negative correlation with markers of bone breakdown at baseline, although not with bone mineral density, and ghrelin infusion has no acute effect on these markers [57, 58].

GLP-2 is a 33-amino acid peptide expressed mainly in the L cells of the small intestine. GLP-2 is secreted in response to nutrient ingestion and its physiologic function appears to be to regulate intestinal motility and stimulate intestinal nutrient ingestion and its physiologic function appears to be to regulate intestinal motility and stimulate intestinal nutrient ingestion. GLP-2 receptors are expressed in osteoblasts and the administration of GLP-2 to human subjects inhibits bone resorption and increases bone mass [60–62].

5.2. Pancreatic hormones

Insulin has long been considered the main anabolic hormone, stimulating bone formation in vitro. However, in vivo, although insulin infusion is known to decrease markers of bone breakdown, this effect is only about 30% of the decline in resorption markers that occurs postprandially. In fact, it has been suggested that this effect is due to hypoglycemia and the attendant impairment in skeletal cellular activity rather than to a direct antiresorptive effect [63].

Amylin is a 37-amino acid hormone cosecreted from the pancreatic β cells with insulin in response to a meal. Amylin lowers serum calcium, inhibits bone resorption, and increases bone mass in mice [64–66].

Adrenomedullin is a 52-amino acid peptide related to amylin; it is expressed in the adrenal medulla, vasculature brain, kidney, and bone [67]. Adrenomedullin stimulates osteoblastic proliferation and injection of adrenomedullin to mice increases bone formation and strength without a major effect on bone breakdown [68, 69].

Preptin is a 37-amino acid peptide cosecreted from the pancreatic islet with amylin and insulin. Preptin stimulated osteoblastic proliferation, and the daily injection of this peptide for five days over the calvaria resulted in increased bone area and mineralized surface through increased bone formation rather than through inhibition of bone breakdown [70].

5.3. Adipocytely-secreted hormones

Adiponectin is a 247-amino acid protein strongly expressed in mature adipocytes (particularly in subcutaneous versus visceral adipocytes) and the levels correlate with the degree of differentiation [71]. Thus, PPARγ agonists (e.g., thiazolidinediones) are potent stimulators of adiponectin expression. Adiponectin suppresses both cell proliferation and release of other inflammatory cytokines [71]. Both the adiponectin protein and its receptor are expressed in osteoblasts and osteoclasts, and its effects on bone turnover are complex [72, 73]. In humans, adiponectin levels have been shown to be negatively correlated with bone mineral density [74], particularly in postmenopausal female patients [75].

Resistin is a 137-amino acid protein secreted from adipocytes [76]. In addition to adipocytes, resistin is also expressed in pancreas, brain, and bone marrow. In the adipocyte, resistin expression is regulated by PPARγ with PPARγ agonists such as rosiglitazone resulting in an inhibition of resistin expression [77]. Resistin secretion results in insulin resistance. In the bone, resistin is expressed in osteoblast, osteoclast, and mesenchymal stem cells [76] and resistin levels are negatively correlated with bone mineral density [78].

5.4. Glucose-dependent insulinotropic peptide

There are two major intestinal hormones that potentiate glucose-induced insulin secretion (incretin effect), that is, GIP and glucagon-like peptide-1 (GLP-1). GLP-1 receptors are not present in bone cells [79]. GIP was first identified in the 1970’s as a hormone secreted by cells in the enteric endocrine system (K cells) in the proximal small intestine. Because this 42-amino acid peptide was found to inhibit gastric acid secretion, it was initially named gastric inhibitory peptide (GIP) [80]. Subsequent studies demonstrated that GIP effects on inhibiting gastric acid secretion did not occur at physiological concentrations, in contrast to GIP effects on potentiating glucose-induced insulin secretion. Thus GIP’s name was changed to glucose-dependent insulinotropic peptide. Our data and resulting publications demonstrate that GIP also serves as an important anabolic signal for bone, stimulating bone formation and inhibiting bone breakdown. To summarize our GIP data in vitro, (1) GIP receptors are present in both osteoblasts and osteoclasts [81, 82]; (2) in osteoblasts, GIP increases collagen type I synthesis and increases alkaline phosphatase activity [81]; (3) in osteoblasts, GIP stimulates proliferation [81]; and (4) in osteoclasts, GIP inhibits PTH-induced long bone resorption and decreases osteoclastic resorption pit depth [82]. In vivo studies, (5) GIP receptor knockout mice have a lower bone mass, decreased serum markers of bone formation, and increased markers of bone breakdown [83], consistent with data
published by others, [84] and (6) GIP-overexpressing transgenic mice have increased bone mass, lower serum markers of bone breakdown, and increased markers of bone formation [85].

The GIP receptor knockout mouse was developed by Miyawaki and colleagues [86], and it is an interesting animal model linking nutritional hormones and bone formation. These knockout mice are not different from control mice in their weight, basal insulin, glucose levels, or in their insulin response to an intraperitoneal glucose tolerance test. However, blood glucose levels, in response to an oral glucose tolerance test or a high-fat diet, are higher in the knockout mice compared to controls, and the higher blood glucose levels in the knockout mice are associated with lower insulin levels. A subsequent report, also by Miyawaki et al. [87], demonstrates that although normal mice fed a high-fat diet gained weight, GIP receptor knockout mice were protected from the large weight gain associated with this diet. Interestingly, GIPR knockout mice fed a high-fat diet had lower leptin levels than control mice fed a high-fat diet (2-fold increase from basal in GIPR−/− versus 4-fold increase in WT). Furthermore, if GIPR−/− mice are crossed with the obese model Lepob/Lepob to generate double homozygous mice, these double homozygous mice are partially protected from the large weight gain associated with this diet. The authors conclude that under normal conditions an excessive amount of fat in the diet leads to GIP hypersecretion; this in turn leads to more adiposity, resulting in obesity and insulin resistance.

In our studies, we found that if the GIP receptor is downregulated, bone mass decreases and bone marrow adipocyte content increases [85]. These findings would suggest the possibility of direct GIP effects on MSCs. In fact, we have demonstrated that GIP receptors are present on MSCs and that stimulation of these cells with GIP promotes osteoblastic differentiation [88].

6. LEPTIN

The cytokine-like hormone leptin is recognized as a powerful regulator of appetite and energy balance [89]. Adipocytes are the primary source of leptin in the body and as such leptin plays an important role as a signal of energy status to the brain [90]. Leptin produced by peripheral body fat enters the circulation and crosses the blood-brain barrier to reach leptin receptors located in the hypothalamus. Leptin binding to the long form of the leptin receptor induces the expression of anorexigenic neuropeptides such as cocaine-amphetamine-related transcript (CART) and alpha-melanocyte-stimulating hormone (α-MSH), and suppresses the activity of orexigenic genes such as neuropeptide Y (NPY) and agouti-related peptide (AgRP), that are involved in regulating food intake [91]. Leptin also regulates sympathetic outflows and functions as a beta-adrenergic agonist [92], and intrahypothalamic injections of leptin induce apoptosis of adipocytes in both peripheral fat and bone marrow [93]. Adipocytes express beta-adrenergic receptors, particularly beta 3 [94], and activation of these receptors can induce apoptosis through activation of a tyrosine kinase pathway [95].

Leptin also appears to regulate adipocyte populations in bone marrow directly, in addition to the central effects of leptin on adipocyte apoptosis. Leptin-deficient ob/ob mice show a significant increase in bone marrow adipocytes compared to lean mice [96], and peripheral leptin injections decrease the population of bone marrow adipocytes in ob/ob mice and increase bone formation [97]. As discussed above, the loss of bone marrow adipocytes with peripheral leptin treatment may be a centrally mediated effect, but the increased osteogenic differentiation and increased endocortical bone formation are more consistent with a direct effect of leptin on osteogenic differentiation [89]. Bone marrow stromal cells (BMSCs) express leptin receptors, and leptin binding increases the expression of osteogenic genes and directs
BMSCs to the osteogenic rather than the adipogenic pathway [98]. In studies by Thomas et al. [98], leptin did not alter PPAR-γ or Cbfa-1 expression despite increasing osteogenesis and decreasing adipogenesis presumably by acting at a later stage in osteoblast differentiation. Bone marrow adipocytes secrete leptin themselves [99], raising the possibility that leptin may play a role in autocrine or paracrine signaling within the bone marrow microenvironment. We have found that age-associated bone loss in mice is associated with decreased serum leptin [100], and as noted earlier, aging is associated with bone loss and an increased accumulation of bone marrow adipocytes. These data suggest that leptin treatment, in conditions of increased leptin sensitivity (see below), may have significant potential for increasing bone formation and decreasing marrow adipogenesis with aging.

7. MYOSTATIN

Myostatin was initially identified as a factor regulating myogenic differentiation because its expression was localized to developing skeletal muscle, and because myostatin loss-of-function was observed to have dramatic effects on muscle mass in mice. It was, however, also noted that mice lacking myostatin showed decreased body fat [101, 102], and
myostatin deficiency decreased adiposity in leptin-deficient ob/ob mice [102]. This was thought to be an indirect effect of the increased muscle mass on metabolism. Since that time, we and others have found that myostatin deficiency inhibits adipogenesis in vivo, even when mice are fed a high-fat diet [103]. Transgenic overexpression of myostatin propeptide, which inhibits myostatin signaling, also inhibits body fat gain with a high-fat diet [104]. Similar alterations in myostatin signaling are associated with changes in body fat among humans. A child with a naturally occurring mutation in the myostatin gene was shown to have increased muscle mass as well as decreased subcutaneous fat [105]. Weight loss in morbidly obese subjects was associated with significant downregulation of myostatin mRNA in muscle biopsies, suggesting a role for myostatin in energy partitioning between protein and fat [106].

Although the in vivo data consistently show that myostatin has an adipogenic effect, and that myostatin deficiency has an anti-adipogenic effect, the in vitro data are less clear. Myostatin has been observed to promote adipogenesis in multipotent muscle C3H 10T (1/2) mesenchymal stem cells [107], but myostatin can also inhibit adipocyte differentiation in 3T3-L1 mouse preadipocytes [108] and inhibit BMP-7-mediated adipogenesis by binding to the same receptor as BMP-7, the activin IIB (ActRIIB) receptor [109]. These data suggest that the decreased fat mass of myostatin-deficient animals is simply an indirect effect of increased muscle mass since other mouse models showing increased muscle mass, such as transgenic mice overexpressing Akt [110] and Ski [111], also show decreased fat mass. However, we have recently identified expression of the myostatin receptor in bone marrow-derived mesenchymal stem cells (BMSCs), and found that BMSCs from myostatin-deficient mice demonstrate increased osteogenic differentiation and decreased adipogenic differentiation [112]. There are not many studies examining the effect of myostatin on PPAR-γ expression. A study by Artaza et al. [107] demonstrated that myostatin increased expression of C/EBP alpha and adipogenesis in mesenchymal stem cells, suggesting a myostatin effect on PPAR-γ, although they did not actually examine PPAR-γ expression. These data are consistent with previous reports showing increased bone mineral density in the bones of myostatin-deficient animals [113–115]. Furthermore, these data from bone marrow cells provide further evidence that myostatin is an adipogenic factor, as well as one that suppresses myogenesis and perhaps osteogenesis. In contrast, a study by Hirai et al. [116] found that myostatin inhibited PPAR-γ and C/EBP alpha expression in bovine preadipocytes. Thus, myostatin effects on PPAR-γ may be cell-type-dependent.

8. GLUCOCORTICOID-INDUCED LEUCINE ZIPPER

GILZ, which is also induced by estrogen and sonic hedgehog (Shh), is a new member of the leucine zipper protein [117, 118] and belongs to the TGF-β-stimulated clone-22 (TSC-22) family of transcription factors [119, 120]. Members of this family of proteins contain three distinct domains: an N-terminus TSC box, a middle leucine zipper domain, and a C-terminus polyproline-rich domain. GILZ was originally identified from dexamethasone-treated murine thymocytes [118]. Recent studies have shown that GILZ is also induced in many tissues (including lung, liver, brain, and kidney) and by the other glucocorticoids that are prescribed frequently in clinic such as methylprednisolone, flucortasone, and hydrocortisone, as well as anti-inflammatory cytokine interleukin-10 (IL-10) in human and murine macrophages [121–123]. Studies carried out in vitro have shown that overexpression of GILZ protected T cells from apoptosis induced by anti-CD3 antibody, but not other apoptosis-inducing agents such as dexamethasone, various doses of ultraviolet irradiation, starvation, or triggering induced by cross-linked anti-Fas monoclonal antibody [118]. However, T-cell-specific transgenic overexpression of GILZ resulted in thymocyte apoptosis ex vivo possibly through downregulation of Bcl-xL [124]. GILZ also inhibits interleukin-2 (IL2)/IL-2 receptor expression (63). This antiapoptotic function is mediated through direct protein-protein interactions between GILZ and NF-kB, and between GILZ and AP-1 (63–67). The direct interactions of GILZ with NF-kB, and GILZ with AP-1, block DNA binding and, therefore, the transcriptional activities of NF-kB and AP-1.

Studies by Shi et al. [125] found that GILZ is rapidly induced by dexamethasone in MSCs and a variety of cell lines, including osteoblasts (2T3), preadipocytes (3T3-L1), and a mesenchymal cell line (C3H10T1/2). It is interesting to note that the induction of GILZ in MSCs and C3H10T1/2 cells seems transient. GILZ can bind specifically to a 40-bp DNA fragment containing a unique tandemly repeated C/EBP-binding element present in the promoter of the PPAR-γ2 gene. Because glucocorticoids induce adipocyte differentiation, and GILZ is induced by glucocorticoids and binds to adipogenic PPAR-γ2 promoter, it was hypothesized that constitutive expression of GILZ would activate PPAR-γ2 expression and enhance adipogenesis. Contrary to expectations, overexpression of GILZ inhibited PPAR-γ2 transcription and blocked adipocyte differentiation of C3H10T1/2 mesenchymal cells and 3T3-L1 preadipocytes. These results demonstrated that GILZ functions as a transcriptional repressor of PPAR-γ2. Studies by Zhang et al. (unpublished data) show that overexpression of GILZ in mouse bone marrow MSCs can enhance MSC osteoblast differentiation. These data suggest that, by modulating PPAR-γ expression, GILZ may serve as an important regulator of the MSC lineage commitment between osteoblast and adipocyte. This role of GILZ may have potential clinic importance since as humans age, the number of adipocytes increase and the number of osteoblasts decrease resulting in weakened bone and age-related osteoporosis and fragility fractures. All these may have direct connection to the increased PPAR-γ expression and activity in aging bone marrow as it is known that aging activates marrow adipogenesis and fat secretes large amounts of cytokines that will, in turn, inhibit osteogenesis as mentioned earlier.

As previously mentioned, the transcriptional activity of PPAR-γ is regulated by phosphorylation (by kinases such as the mitogen-activated protein kinase (MAPK), which activate Jun N-terminal kinase, or JNK, and extracellular signal-regulated kinase 2, or ERK 2), and GILZ can directly interact...
with Raf1, one of the MAPK members, resulting in the inhibition of Raf-1 phosphorylation and, subsequently, the suppression of both MEK/ERK-1/2 phosphorylation and AP-1-dependent transcription [119].

It has been a long standing paradox that glucocorticoids, while required for osteoblast differentiation of primary bone marrow stromal cells in vitro [126–128], induce bone loss in vivo. Since GILZ is induced by glucocorticoids and enhances MSC osteogenesis, we speculate that GILZ is the actual mediator of glucocorticoid action in this process. The possible pathways in which GILZ may convey therapeutic effects of glucocorticoids have been reviewed by Clark and Lasa [129].

Under normal conditions, GC levels fluctuate in response to environmental stressors (flight/flight, abrupt temperature changes, etc.). When the GC level is increased, GILZ is induced and prevents adipogenic differentiation. Under pathophysiological or pharmacological conditions, however, GC is elevated for a prolonged period of time and the negative feedback network is overwhelmed, resulting in harmful GC side effects, such as bone loss.

9. GIP, LEPTIN, MYOSTATIN, AND GILZ AS THERAPEUTIC TARGETS

Adequate nutrition and a positive energy balance are clearly important for bone growth. A reduction in caloric intake will retard growth plate expansion [130]. In addition, if the reduced caloric intake is accompanied by a reduced calcium intake, a shift in the balance between bone formation and resorption occurs, such that bone mass decreases over time [131]. In contrast, an increase in intake and gain in weight are associated with an increase in bone mass. Upon nutrient delivery to the intestine, there is a rapid rise in a number of enteric hormones that serve to inform the target tissues that nutrients are available for anabolic activity. One of these enteric hormones, GLP-2, has already been used to prevent bone loss in postmenopausal patients [62], although no data are available on marrow adiposity. Our data would suggest that GIP is another enteric hormone that can increase bone formation by promoting MSC differentiation into osteoblasts.

One of the challenges in using recombinant leptin therapy to either reduce body weight, suppress appetite, or stimulate bone formation is that most individuals are relatively resistant to exogenous leptin treatment due to relatively high levels of endogenous leptin [89, 96]. However, leptin may have significant effects on bone formation and appetite in conditions where leptin sensitivity is increased with energy deprivation. For example, leptin treatment has been observed to increase serum IGF-1 and serum osteocalcin in women with exercise-induced hypothalamic amenorrhea [132]. Anorexia nervosa is associated with markedly reduced leptin levels and osteoporosis [133–135] even if less severe, voluntary weight loss is associated with increased rates of bone loss in adults [136, 137]. Leptin treatment may have potential to reverse bone loss with weight loss, as well as maintenance of reduced weight following weight loss [138].

Treatment of normal rodents and dystrophin-deficient mdx mice with factors that block myostatin signaling, such as a soluble myostatin receptor, a propeptide, or follistatin, showed significant increases in muscle mass and improved muscle regeneration [139, 140]. The myostatin antibody MYO 029 is currently in Phase II clinical trials for treatment of Duchenne muscular dystrophy. To date, myostatin inhibitors have only been tested for their ability to improve muscle regeneration in cases of muscular dystrophy and acute injury, and their potential for inhibiting body fat gain and stimulating bone formation remains relatively unexplored. We expect that myostatin inhibitors have significant potential as novel therapies for decreasing adiposity and also improving bone formation and bone strength. Moreover, as noted earlier in this paper, glucocorticoids play a major role in stimulating bone marrow adipogenesis, and the myostatin promoter is known to have a glucocorticoid response element [141]. Myostatin deficiency inhibits muscle atrophy with glucocorticoid treatment [142], and myostatin inhibitors may be useful for attenuating muscle atrophy and bone loss with prolonged use of glucocorticoids.

Bone cells are derived from marrow MSCs, and the best way to increase the number of bone-forming cells is to modulate differentiation pathways so that more MSCs are directed to the osteoblastogenesis pathway. The PPAR-γ pathway not only regulates adipocyte differentiation, but also inhibits osteoblast differentiation from mesenchymal progenitors [31], suggesting the possibility of interrupting the PPAR-γ pathway as a novel treatment of osteoporosis. GILZ, induced transiently by GC, is a sequence-specific transcriptional repressor of PPAR-γ [143]. No transcriptional repressors that can bind specifically to the promoter of PPAR-γ have been reported so far. Thus, GILZ may be a novel therapeutic target for drug development for a variety of conditions characterized by an altered adipocyte/osteoblast balance.

In summary, current therapeutic targets for prevention and treatment of osteoporosis involve anabolic agents stimulating osteoblastic activity or antiresorptive agents targeting the osteoclasts. Our data would suggest that modulating the MSC differentiation pathway, particularly via inhibition of the PPAR-γ2 receptor, thus favoring osteoblastic instead of adipocytic differentiation, might be an attractive therapeutic target for prevention and treatment of osteoporosis.

ACKNOWLEDGMENTS

This work was supported in part by funding from the National Institutes of Health (R01DK058680, C. M. Isales; R01 AR049717, M. Hamrick) and the American Heart Association (X. Shi).

REFERENCES

[1] C. Blanquart, O. Fruchart, B. Fruchart, B. Steals, and C. Glineur, “ Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 85, no. 2–5, pp. 267–273, 2003.

[2] S. R. Farmer, “ Regulation of PPARγ activity during adipogenesis,” International Journal of Obesity, vol. 29, suppl. 1, pp. 13–16, 2005.
[3] S. L. Gray, E. Dalla Nora, and A. J. Vidal-Puig, “Mouse models of PPAR-γ deficiency: dissecting PPAR-γ's role in metabolic homeostasis,” *Biochemical Society Transactions*, vol. 33, no. 5, pp. 1053–1058, 2005.

[4] M. Gurnel, “Peroxisome proliferator-activated receptor gamma and the regulation of adipocyte function,” *Best Practice & Research. Clinical Endocrinology & Metabolism*, vol. 19, no. 4, pp. 501–523, 2005.

[5] B. P. Kota, T. H. Huang, and B. D. Roufogalis, “An overview on biological mechanisms of PPARs;” *Pharmacological Research*, vol. 51, no. 2, pp. 58–94, 2005.

[6] M. A. Lazar, “PPAR gamma, 10 years later,” *Biochimie*, vol. 87, no. 1, pp. 9–13, 2005.

[7] M. Lehrke and M. A. Lazar, “The many faces of PPARgamma,” *Cell*, vol. 123, no. 6, pp. 993–999, 2005.

[8] S. Miard and L. Fajas, “Atypical transcriptional regulators and cofactors of PPAR-γ,” *International Journal of Obesity*, vol. 29, suppl. 1, pp. 10–12, 2005.

[9] L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome proliferator-activated receptors and inflammation,” *Pharmacology & Therapeutics*, vol. 110, no. 3, pp. 371–385, 2006.

[10] R. K. Semple, V. K. Chatterjee, and S. O'Rahilly, “PPAR-γ and human metabolic disease,” *The Journal of Clinical Investigation*, vol. 116, no. 3, pp. 581–589, 2006.

[11] B. Staels and J. C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” *Diabetes*, vol. 54, no. 8, pp. 2460–2470, 2005.

[12] N. S. Tán, L. Michalik, B. Desvergne, and W. Wahli, “Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes,” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 93, no. 2–5, pp. 99–105, 2005.

[13] S. Theocharis, A. Margeli, P. Vielh, and G. Kouraklis, “Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators,” *Cancer Treatment Reviews*, vol. 30, no. 6, pp. 545–554, 2004.

[14] R. Mukherjee, L. Jow, G. E. Croston, and J. R. Pater- niti Jr., “Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPAR-γ2 versus PPAR-γ1 and activation with retinoid X receptor agonists and antagonists,” *The Journal of Biological Chemistry*, vol. 272, no. 12, pp. 8071–8076, 1997.

[15] Y. Zhu, C. Qi, J. R. Korenberg, et al., “Structural organization of mouse peroxisome proliferator-activated receptor-γ (mPPAR-γ) gene: alternative promoter use and different splicing yield two mPPAR-γ isoforms,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, no. 17, pp. 7921–7925, 1995.

[16] Y. Barak, M. C. Nelson, E. S. Ong, et al., “PPAR γ is required for placental, cardiac, and adipose tissue development,” *Molecular Cell*, vol. 4, no. 4, pp. 585–595, 1999.

[17] E. D. Rosen, P. Sarraf, A. E. Troy, et al., “PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro,” *Molecular Cell*, vol. 4, no. 4, pp. 611–617, 1999.

[18] P. Tontonoz, E. Hu, R. A. Graves, A. L. Budavari, and B. M. Spiegelman, “mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer,” *Genes & Development*, vol. 8, no. 10, pp. 1224–1234, 1994.

[19] A. Chawla, E. J. Schwarz, D. D. Dimaculangan, and M. A. Lazar, “Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation,” *Endocrinology*, vol. 135, no. 2, pp. 798–800, 1994.

[20] K. Schoonjans, J. Peinado-Onsurbe, A. M. Lefebvre, et al., “PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene,” *The EMBO Journal*, vol. 15, pp. 5336–5348, 1996.

[21] P. Tontonoz, E. Hu, J. Devine, E. G. Beale, and B. M. Spiegelman, “PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene,” *Molecular and Cellular Biology*, vol. 15, no. 1, pp. 351–357, 1995.

[22] B. I. Frohnert, T. Y. Hui, and D. A. Bernlohr, “Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene,” *The Journal of Biological Chemistry*, vol. 274, no. 7, pp. 3970–3977, 1999.

[23] C. W. Miller and J. M. Ntambi, “Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase 1 gene expression,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 93, no. 18, pp. 9443–9448, 1996.

[24] B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-Deoxy-Δ 12, 14-prostaglandin j 2 is a ligand for the adipocyte determination factor PPAR-γ,” *Cell*, vol. 83, no. 5, pp. 803–812, 1995.

[25] S. A. Kliever, J. M. Lenhard, T. M. Willson, I. Patel, D. Morris, and J. M. Lehmann, “A prostaglandin j2 metabolite binds peroxisome proliferator-activated receptor-γ and promotes adipocyte differentiation,” *Cell*, vol. 83, no. 5, pp. 813–819, 1995.

[26] S. Altiok, M. Xu, and B. M. Spiegelman, “PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A,” *Genes & Development*, vol. 11, no. 15, pp. 1987–1998, 1997.

[27] J. M. Gimble, C. E. Robinson, X. Wu, et al., “Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells,” *Molecular Pharmacology*, vol. 50, no. 5, pp. 1087–1094, 1996.

[28] E. Hu, P. Tontonoz, and P. M. Spiegelman, “Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR-γ and C/EBPβ,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 92, pp. 9856–9860, 1995.

[29] J. M. Lehmann, L. B. Moore, T. A. Smith- Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliever, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma),” *The Journal of Biological Chemistry*, vol. 270, no. 50, pp. 12953–12956, 1995.

[30] P. Tontonoz, E. Hu, and P. M. Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor,” *Cell*, vol. 79, no. 7, pp. 1147–1156, 1994.

[31] T. Akune, S. Ohba, S. Kamekura, et al., “PPAR-γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” *The Journal of Clinical Investigation*, vol. 113, no. 6, pp. 846–855, 2004.

[32] S. P. Bruder, N. Jaiswal, and S. E. Haynesworth, “Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation,” *Journal of Cellular Biochemistry*, vol. 64, no. 2, pp. 278–294, 1997.

[33] J. J. Minguell, A. Erices, and P. Conget, “Mesenchymal stem cells,” *Experimental Biology and Medicine*, vol. 226, pp. 507–520, 2001.
[34] M. F. Pittenger, A. M. Mackay, S. C. Beck, et al., “ multilineage potential of adult human mesenchymal stem cells,” *Science*, vol. 284, no. 5411, pp. 143–147, 1999.

[35] D. J. Prockop, “Marrow stromal cells as stem cells for non-hematopoietic tissues,” *Science*, vol. 276, no. 5309, pp. 71–74, 1997.

[36] S. Akhdjoudj, F. Lasmoles, B. O. Oyajobi, A. Lomri, P. Delannoy, and P. J. Marie, “ Reciprocal control of osteoblast/chondroblast and osteoblast/adipocyte differentiation of multipotent clonal human marrow stromal F/STRO-1(+) cells,” *Journal of Cellular Biochemistry*, vol. 81, no. 1, pp. 23–38, 2001.

[37] T. Akune, S. Ohba, S. Kamekura, et al., “ PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” *The Journal of Clinical Investigation*, vol. 113, no. 6, pp. 846–855, 2004.

[38] J. N. Beresford, J. H. Bennett, C. Devlin, P. S. Leboy, and M. E. Owen, “ Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures,” *Journal of Cell Science*, vol. 83, no. 102, pt. 2, pp. 341–351, 1992.

[39] F. Gori, T. Thomas, K. C. Hicok, T. C. Spelsberg, and B. L. Riggs, “ Differentiation of human marrow stromal precursor cells: bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation,” *Journal of Bone and Mineral Research*, vol. 14, pp. 1522–1535, 1999.

[40] R. K. Jaiswal, N. Jaiswal, S. P. Bruder, G. Mbalaviele, D. R. Marshak, and M. F. Pittenger, “ Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase,” *The Journal of Biological Chemistry*, vol. 275, no. 13, pp. 9645–9652, 2000.

[41] B. Becka-Czernik, E. J. Moerman, D. F. Grant, J. M. Lehmann, S. C. Manolagas, and R. L. Jilka, “ Divergent effects of selective peroxisome proliferator-activated receptor-γ ligands on adipocyte versus osteoblast differentiation,” *Endocrinology*, vol. 143, no. 6, pp. 2376–2384, 2002.

[42] M. E. Nutall and J. M. Gimble, “ Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis?” *Bone*, vol. 27, no. 2, pp. 177–184, 2000.

[43] A. C. Maurin, P. M. Chavassieux, L. Frappart, P. D. Delmas, C. M. Serre, and P. J. Meinier, “ Influence of mature adipocytes on osteoblast proliferation in human primary co-cultures,” *Bone*, vol. 26, no. 5, pp. 485–489, 2000.

[44] S. K. Fried, D. A. Bunkin, and A. S. Greenberg, “ Omental and subcutaneous adipose tissue of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 83, no. 3, pp. 847–850, 1998.

[45] S. Verma, J. H. Rajaratnam, J. Denton, J. A. Hoyland, and R. J. Byers, “ Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis,” *Journal of Clinical Pathology*, vol. 55, no. 9, pp. 693–698, 2002.

[46] J. Justesen, K. Stenderup, and M. S. Kassem, “ Mesenchymal stem cells. Potential use in cell and gene therapy of bone loss caused by aging and osteoporosis,” *Ugeskrift for Laeger*, vol. 163, no. 40, pp. 5491–5495, 2001.

[47] A. Grey, M. Bolland, G. Gamble, et al., “ The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 92, no. 4, pp. 1305–1310, 2007.

[48] A. V. Schwartz, “Diabetes, TZDs, and Bone,” *A Review of the Clinical Evidence*, vol. 2006, Article ID 24502, 2006.

[49] S. Miard and L. Fajas, “ Atypical transcriptional regulators and cofactors of PPARγ,” *International Journal of Obesity*, vol. 29, suppl. 1, pp. 10–12, 2005.

[50] E. D. Rosen and L. Fajas, “ Atypical transcriptional regulators and cofactors of PPARγ,” *Prostaglandins, Leukotrienes, and Essential Fatty Acids*, vol. 73, no. 1, pp. 31–34, 2005.

[51] C. W. Park, H. W. Kim, S. H. Ko, et al., “ Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice,” *Journal of the American Society of Nephrology*, vol. 18, no. 4, pp. 1227–1238, 2007.

[52] J. A. Glowes, S. Klosa, R. Eastell, et al., “ Potential role of pancreatic and enteric hormones in regulating bone turnover,” *Journal of Bone and Mineral Research*, vol. 20, no. 9, pp. 1497–1506, 2005.

[53] I. R. Reid, J. Cornish, and P. A. Baldock, “ Nutrition-related peptides and bone homeostasis,” *Journal of Bone and Mineral Research*, vol. 21, no. 4, pp. 495–500, 2006.

[54] N. A. Tritos and E. G. Kokkotou, “ The physiology and potential clinical applications of ghrelin, a novel peptide hormone,” *Mayo Clinic Proceedings*, vol. 81, no. 5, pp. 653–660, 2006.

[55] N. Fukushima, R. Hanada, H. Teranishi, et al., “ Ghrelin directly regulates bone Formation,” *Journal of Bone and Mineral Research*, vol. 20, no. 5, pp. 790–798, 2005.

[56] S. W. Kim, S. J. Her, S. J. Park, et al., “ Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells,” *Bone*, vol. 37, no. 3, pp. 359–369, 2005.

[57] M. S. Huda, B. H. Durham, S. P. Wong, et al., “ Lack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects,” *Bone*, vol. 41, no. 3, pp. 406–413, 2007.

[58] L. A. Weiss, C. Langenberg, E. Barrett-Connor, et al., “ Ghrelin and bone: is there an association in older adults? the Rancho Bernardo study,” *Journal of Bone and Mineral Research*, vol. 21, no. 5, pp. 752–757, 2006.

[59] L. L. Baggio and D. J. Drucker, “ Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2,” *Best Practice & Research. Clinical Endocrinology & Metabolism*, vol. 18, no. 4, pp. 531–554, 2004.

[60] D. B. Henriksen, P. Alexandersen, N. H. Bjarnason, et al., “ Role of gastrointestinal hormones in postprandial reduction of bone resorption,” *Journal of Bone and Mineral Research*, vol. 18, no. 12, pp. 2180–2189, 2003.

[61] D. B. Henriksen, P. Alexandersen, I. Bryjalsen, et al., “ Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2,” *Bone*, vol. 34, no. 1, pp. 140–147, 2004.

[62] D. B. Henriksen, P. Alexandersen, B. Hartmann, et al., “ Disassociation of bone resorption and formation by GLP-2: A 14-day study in healthy postmenopausal women,” *Bone*, vol. 40, no. 3, pp. 723–729, 2007.

[63] N. H. Bjarnason, E. E. Henriksen, P. Alexandersen, S. Christgau, D. B. Henriksen, and C. Christiansen, “ Mechanism of circadian variation in bone resorption,” *Bone*, vol. 30, no. 1, pp. 307–313, 2002.

[64] J. Cornish, K. E. Callon, A. R. King, G. J. S. Cooper, and I. R. Reid, “ Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice,” *The American Journal of Physiology Links*, vol. 275, no. 4, pp. E694–E699, 1998.
[65] J. Cornish, K. E. Gallon, C. Q. Lin, et al., “Dissociation of the effects of amylin on osteoblast proliferation and bone resorption,” The American Journal of Physiology, vol. 274, no. 5, pp. E827–E833, 1998.

[66] M. Zaidi, V. S. Shankar, C. L.-H. Huang, M. Paizanas, and S. R. Bloom, “Amylin in bone conservation: current evidence and hypothetical considerations,” Trends in Endocrinology and Metabolism, vol. 4, no. 8, pp. 255–259, 1993.

[67] J. Cornish and I. R. Reid, “Effects of amylin and adrenomedullin on the skeleton,” Journal of Musculoskeletal & Neuronal Interactions, vol. 2, no. 1, pp. 15–24, 2001.

[68] J. Bronsky, R. Prusa, and J. Nevoral, “The role of amylin and related peptides in osteoporosis,” Clinica Chimica Acta: International Journal of Clinical Chemistry, vol. 373, no. 1–2, pp. 9–16, 2006.

[69] J. Cornish, K. E. Gallon, U. Bava, et al., “Systemic administration of adrenomedullin (27-52) increases bone volume and strength in male mice,” Journal of Endocrinology, vol. 170, no. 1, pp. 251–257, 2001.

[70] J. Cornish, K. E. Gallon, U. Bava, et al., “Preptin, another peptide product of the pancreatic β-cell, is osteogenic in vitro and in vivo,” American Journal of Physiology: Endocrinology and Metabolism, vol. 292, no. 1, pp. E117–E122, 2007.

[71] A. Koerner and J. Kratzsch, “Kiess W. Adipocytokines: peptide receptors,” Endocrinology, vol. 141, no. 3, pp. 1228–1235, 2000.

[72] Q. Zhong, T. Itokawa, S. Srithar, et al., “Effects of glucose-dependent insulinotropic peptide on osteoclast function,” American Journal of Physiology—Endocrinology and Metabolism, vol. 292, no. 2, pp. E543–E548, 2007.

[73] D. Xie, H. Cheng, M. Hamrick, et al., “Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover,” Bone, vol. 37, no. 6, pp. 759–769, 2005.

[74] K. Tsukiyama, T. Yamada, C. Yamada, et al., “Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion,” Molecular Endocrinology, vol. 20, no. 7, pp. 1644–1651, 2006.

[75] X. Shi, M. Hamrick, B. Kang, et al., “Glucose-Dependent Insulinotropic Peptide—Overexpressing Transgenic Mice Have Increased Bone Mass,” Bone, vol. 40, pp. 1352–1360, 2007.

[76] M. Miyawaki, Y. Yamada, H. Yano, et al., “Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 26, pp. 14843–14847, 1999.

[77] M. Miyawaki, Y. Yamada, N. Ban, et al., “Inhibition of gastric inhibitory polypeptide signaling prevents obesity,” Nature Medicine, vol. 8, pp. 738–742, 2002.

[78] R. L. Leshan, M. Björnholm, H. Münzberg, and M. G. Myers Jr., “Leptin receptor signaling and action in the central nervous system,” Obesity (Silver Spring), vol. 14, suppl. 5, pp. 208–212, 2006.

[79] B. M. Spiegelman and J. S. Flier, “Obesity and the regulation of energy balance,” Cell, vol. 104, no. 4, pp. 531–543, 2001.

[80] S. Collins, C. M. Kühn, A. E. Petro, A. G. Swick, B. A. Chrunyk, and R. S. Surwit, “Role of leptin in fat regulation,” Nature, vol. 380, no. 6576, p. 677, 1996.

[81] M. Hamrick, M. Della Fera, Y-H. Choi, D. Hartzell, C. Pennington, and C. Baile, “Injections of leptin into rat ventromedial hypothalamus increase adipocyte apoptosis in peripheral fat and in bone marrow,” Cell and Tissue Research, vol. 327, no. 1, pp. 133–141, 2007.

[82] S. Collins and R. S. Surwit, “The β-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis,” Recent Progress in Hormone Research, vol. 56, pp. 309–328, 2001.

[83] Y. C. Ma and X. Y. Huang, “Novel signaling pathway through the β-adrenergic receptor,” Trends in Cardiovascular Medicine, vol. 12, no. 1, pp. 46–49, 2002.

[84] M. W. Hamrick, C. Pennington, D. Newton, D. Xie, and C. Isales, “Leptin deficiency produces contrasting phenotypes in bones of the limb and spine,” Bone, vol. 34, no. 3, pp. 376–383, 2004.

[85] M. W. Hamrick, M. A. Della-Fera, Y. H. Choi, C. Pennington, D. Hartzell, and C. A. Baile, “Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice,” Journal of Bone and Mineral Research, vol. 20, no. 6, pp. 994–1001, 2005.

[86] T. Thomas, E. Gori, S. Khosla, M. D. Jensen, B. Burguera, and B. L. Riggs, “Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit
hypertrophy,” Endocrinology, vol. 140, no. 4, pp. 1630–1638, 1999.

[99] P. Laharrague, D. Larrouy, A. M. Fontanilles, et al., “High expression of leptin by human bone marrow adipocytes in primary culture,” FASEB Journal, vol. 12, no. 9, pp. 747–752, 1998.

[100] M. W. Hamrick, K. H. Ding, C. Pennington, et al., “Age-related loss of muscle mass and bone strength in mice is associated with a decline in physical activity and serum leptin,” Bone, vol. 39, no. 4, pp. 845–853, 2006.

[101] J. Lin, H. B. Arnold, M. A. Della-Fera, M. J. Azain, D. L. Hartzell, and C. A. Baile, “Myostatin knockout in mice increases myogenesis and decreases adipogenesis,” Biochemical and Biophysical Research Communications, vol. 291, no. 3, pp. 701–706, 2002.

[102] A. C. McPherson and S. J. Lee, “Suppression of body fat accumulation in myostatin-deficient mice,” The Journal of Clinical Investigation, vol. 109, pp. 595–601, 2002.

[103] M. W. Hamrick, C. Pennington, C. N. Webb, and C. M. Isales, “Resistance to body fat gain in double-muscled mice fed a high-fat diet,” International Journal of Obesity, vol. 30, no. 5, pp. 868–870, 2006.

[104] B. Zhao, R. J. Wall, and J. Yang, “Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance,” Biochemical and Biophysical Research Communications, vol. 337, no. 1, pp. 248–255, 2005.

[105] M. Schuelke, K. R. Wagner, L. E. Stolz, et al., “Myostatin mutation associated with gross muscle hypertrophy in a child,” The New England Journal of Medicine, vol. 350, no. 26, pp. 2682–2688, 2004.

[106] G. Milan, E. Dalla Nora, C. Pilon, et al., “Changes in muscle myostatin expression in obese subjects after weight loss,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 6, pp. 2724–2727, 2004.

[107] J. N. Artaza, S. Bhasin, T. R. Magee, et al., “Myostatin inhibits myogenesis and promotes adipogenesis in C3H 10T(1/2) mesenchymal multipotent cells,” Endocrinology, vol. 146, no. 8, pp. 3547–3557, 2005.

[108] H. S. Kim, L. Liang, R. G. Dean, D. B. Hausman, D. L. Hartzell, and C. A. Baile, “Inhibition of preadipocyte differentiation by myostatin treatment in 3T3-L1 cultures,” Molecular and Cellular Biology, vol. 281, no. 4, pp. 902–906, 2001.

[109] A. Rebbaapragada, H. Benchabane, J. L. Wrana, A. J. Celeste, and L. Attisano, “Myostatin signals through a transforming growth factor β-like signaling pathway to block adipogenesis,” Molecular and Cellular Biology, vol. 23, no. 20, pp. 7230–7242, 2003.

[110] K. M. Lai, M. Gonzalez, W. T. Poueymirou, et al., “Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy,” Molecular and Cellular Biology, vol. 24, no. 21, pp. 9295–9304, 2004.

[111] P. Sutrave, A. M. Kelly, and S. H. Hughes, “ski can cause selective growth of skeletal muscle in transgenic mice,” Genes & Development, vol. 4, no. 9, pp. 1462–1472, 1990.

[112] M. W. Hamrick, X. Shi, W. Zhang, et al., “Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading,” Bone, vol. 40, no. 6, pp. 1544–1553, 2007.

[113] M. Hamrick, “Increased bone mineral density in the femora of GDF8 knockout mice,” The Anatomical Record Part A: Discoveries in Molecular, Cellular, and Evolutionary Biology, vol. 272A, no. 1, pp. 388–391, 2003.

[114] M. W. Hamrick, C. Pennington, and C. D. Byron, “Bone architecture and disc degeneration in the lumbar spine of mice lacking GDF-8 (myostatin),” Journal of Orthopaedic Research, vol. 21, no. 6, pp. 1025–1032, 2003.

[115] E. K. Nicholson, S. R. Stock, M. W. Hamrick, and M. J. Ravosa, “Biomaterialization and adaptive plasticity of the temporomandibular joint in myostatin knockout mice,” Archives of Oral Biology, vol. 51, no. 1, pp. 37–49, 2006.

[116] S. Hirai, H. Matsumoto, N. Hino, H. Kawachi, T. Matsui, and H. Yano, “Myostatin inhibits differentiation of bovine preadipocyte,” Domestic Animal Endocrinology, vol. 32, no. 1, pp. 1–14, 2007.

[117] L. Cannarile, O. Zollo, F. D’Adamo, et al., “Cloning, chromosomal assignment and tissue distribution of human GILZ, a glucocorticoid hormone-induced gene,” Cell Death and Differentiation, vol. 8, no. 2, pp. 201–203, 2001.

[118] F. D’Adamo, O. Zollo, R. Moraca, et al., “A new dexamethasone-induced gene of the leucine zipper family protects T lymphocytes from TCR/CD3-activated cell death,” Immunity, vol. 7, no. 6, pp. 803–812, 1997.

[119] E. Ayroldi, O. Zollo, A. Macchiariulo, B. Di Marco, C. Marchetti, and C. Riccardi, “Glucocorticoid-induced leucine zipper inhibits the Raf-extracellular signal-regulated kinase pathway by binding to Raf-1,” Molecular and Cellular Biology, vol. 22, no. 22, pp. 7929–7941, 2002.

[120] M. Shibanuma, T. Kuroki, and K. Nose, “Isolation of a gene encoding a putative leucine zipper structure that is induced by transforming growth factor β I and other growth factors,” The Journal of Biological Chemistry, vol. 267, no. 15, pp. 10219–10224, 1992.

[121] D. Berrebi, S. Bruscoli, N. Cohen, et al., “Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10,” Blood, vol. 101, no. 2, pp. 729–738, 2003.

[122] S. Bruscoli, R. Di Virgilio, V. Donato, et al., “Genomic and non-genomic effects of different glucocorticoids on mouse thymocyte apoptosis,” European Journal of Pharmacology, vol. 529, no. 1–3, pp. 63–70, 2006.

[123] P. Smit, H. Russcher, F. H. de Jong, A. O. Brinkmann, S. W. Lamberts, and J. W. Koper, “Differential regulation of synthetic glucocorticoids on gene expression levels of glucocorticoid-induced leucine zipper and interleukin-2,” Journal of Clinical Endocrinology & Metabolism, vol. 90, no. 5, pp. 2994–3000, 2005.

[124] D. V. Delfino, M. Agostini, S. Spincelli, P. Vito, and C. Riccardi, “Decrease of Bcl-xL and augmentation of thymocyte apoptosis in GILZ overexpressing transgenic mice,” Blood, vol. 104, no. 13, pp. 4134–4141, 2004.

[125] X. Shi, W. Shi, Q. Li, et al., “A glucocorticoid-induced leucine-zipper protein, GILZ, inhibits adipogenesis of mesenchymal cells,” EMBO Reports, vol. 4, no. 4, pp. 374–380, 2003.

[126] J. N. Beresford, C. J. Joyner, C. Devlin, and J. T. Tripplett, “The effects of dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic differentiation of human marrow stromal cells in vitro,” Archives of Oral Biology, vol. 39, no. 11, pp. 941–947, 1994.

[127] S. L. Cheng, J. W. Yang, L. Rífas, S. F. Zhang, and L. V. Avioli, “Differentiation of human bone marrow osteogenic stromal cells in vitro: induction of the osteoblast phenotype by dexamethasone,” Endocrinology, vol. 134, no. 1, pp. 277–286, 1994.
128. P. S. Leboy, J. N. Beresford, C. Devlin, and M. E. Owen, “Dexamethasone induction of osteoblast mRNAs in rat marrow stromal cell cultures,” *Journal of Cellular Physiology*, vol. 146, no. 3, pp. 370–378, 1991.

129. A. R. Clark and M. Lasa, “Crosstalk between glucocorticoids and mitogen-activated protein kinase signalling pathways,” *Current Opinion in Pharmacology*, vol. 3, no. 4, pp. 404–411, 2003.

130. C. Heinrichs, M. Colli, J. A. Yanovski, et al., “Effects of fasting on the growth plate: systemic and local mechanisms,” *Endocrinology*, vol. 138, no. 12, pp. 5359–5365, 1997.

131. A. F. Stewart and A. E. Broadus, “Mineral metabolism,” in *Endocrinology and Metabolism*, P. Felig, J. D. Baxter, A. E. Broadus, and L. A. Frohman, Eds., pp. 1317–1453, McGraw-Hill, New York, NY, USA, 2nd edition, 1987.

132. C. K. Welt, J. L. Chan, J. Bullen, et al., “Recombinant human leptin in women with hypothalamic amenorrhea,” *The New England Journal of Medicine*, vol. 351, no. 10, pp. 987–997, 2004.

133. B. A. Kaufman, M. P. Warren, J. E. Dominguez, J. Wang, S. B. Heymsfield, and R. N. Pierson, “Bone density and amenorrhea in ballet dancers are related to a decreased resting metabolic rate and lower leptin levels,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 87, no. 6, pp. 2777–2783, 2002.

134. S. A. Lear, R. P. Pauly, and C. L. Birmingham, “Body fat, caloric intake, and plasma leptin levels in women with anorexia nervosa,” *International Journal of Eating Disorders*, vol. 26, no. 3, pp. 283–288, 1999.

135. J. M. Turner, M. K. Bulsara, B. M. McDermott, G. C. Byrne, R. L. Prince, and D. A. Forbes, “Predictors of low bone density in young adolescent females with anorexia nervosa and other dieting disorders,” *International Journal of Eating Disorders*, vol. 30, no. 3, pp. 245–251, 2001.

136. K. E. Ensrud, R. L. Fullman, E. Barrett-Connor, et al., “Voluntary weight reduction in older men increases hip bone loss: the osteoporotic fractures in men study,” *Journal of Clinical Endocrinology & Metabolism*, vol. 90, no. 4, pp. 1998–2004, 2005.

137. J. M. Johnson, J. W. Maher, I. Samuel, D. Heitshusen, C. Doherty, and R. W. Downs, “Effects of gastric bypass procedures on bone mineral density, calcium, parathyroid hormone, and vitamin D,” *Journal of Gastrointestinal Surgery*, vol. 9, no. 8, pp. 1106–1110, 2005.

138. M. Rosenbaum, R. Goldsmith, D. Bloomfield, et al., “Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight,” *The Journal of Clinical Investigation*, vol. 115, no. 12, pp. 3579–3586, 2005.

139. S. Bogdanovich, K. J. Perkins, T. O. Krag, L. A. Whittemore, and T. S. Khurana, “Myostatin propeptide-mediated amelioration of dystrophic pathophysiology,” *The FASEB Journal*, vol. 19, no. 6, pp. 542–549, 2005.

140. S. I. Lee, L. A. Reed, M. V. Davies, et al., “Regulation of muscle growth by multiple ligands signaling through activin type II receptors,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 50, pp. 18117–18122, 2005.

141. R. Du, Y. F. Chen, X. R. An, et al., “Cloning and sequence analysis of myostatin promoter in sheep,” *DNA Sequence—Journal of DNA Sequencing and Mapping*, vol. 16, no. 6, pp. 412–417, 2005.

142. H. Gilson, O. Schakman, L. Combaret, et al., “Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy,” *Endocrinology*, vol. 148, no. 1, pp. 452–460, 2007.

143. E. Ayroldi, G. Migliorati, S. Bruscoli, et al., “Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor κB,” *Blood*, vol. 98, no. 3, pp. 743–753, 2001.